Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06249165 · ClinicalTrials.gov registry record · Phase 4

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

A Phase 4 study of Atherosclerotic Cardiovascular Disease, sponsored by Duke University.

Active
Registry status
Phase 4
Development phase
130
Enrollment target
20
Study locations

NCT06249165 is a Phase 4 study of Atherosclerotic Cardiovascular Disease that is active but no longer recruiting, run by Duke University. The registered enrollment target is 130 participants, below the 7,562-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06249165, a Phase 4 study of Atherosclerotic Cardiovascular Disease, is active but no longer recruiting, sponsored by Duke University.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
130 participants
Enrollment target
20
Study locations

Study Summary

VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging electronic health records (EHR) in multiple US Healthcare Systems (HCS) to systematically identify those at high risk for and already diagnosed with ASCVD for more expeditious achievement of LDL-C targets.

Conditions Studied

Atherosclerotic Cardiovascular Disease

Interventions

  • DRUG Inclisiran

Study Locations (20)

North Carolina

  • University of North Carolina - Chapel Hill
  • Duke University Medical Center - Durham
  • Wake Forest University - Winston-Salem

California

  • Univ. of California - Irvine - Orange
  • San Francisco General Hospital - San Francisco

Georgia

  • Emory University - Atlanta
  • Wellstar Paulding - Hiram

Maryland

  • JHU - Suburban Hospital - Bethesda
  • Johns Hopkins - Columbia

Missouri

  • University of Missouri - Columbia
  • Washington University - St Louis

Alabama

  • Univ. of Alabama - Birmingham - Birmingham

Illinois

  • Rush University - Chicago

Iowa

  • University of Iowa - Iowa City

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2024-12-16
Est. Completion 2027-02
Phase Phase 4

Sponsor

Duke University

1,725 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06249165

The ClinicalTrials.gov registry entry for NCT06249165 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,562-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (98% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 1 intervention - of which Inclisiran is the first listed.

NCT06249165 reports 20 study locations spanning 14 distinct geographic areas - top geographies include North Carolina, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT06249165 about?

NCT06249165 is a clinical study titled "VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease". VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging electronic health records (EHR) in multiple US Healthcare Systems (HCS) to ...

What is the current status of trial NCT06249165?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 130 participants. The study started on 2024-12-16. Estimated completion is 2027-02.

What conditions does trial NCT06249165 study?

This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease.

What interventions are being tested in trial NCT06249165?

The interventions under investigation include: Inclisiran (DRUG).

Who is sponsoring clinical trial NCT06249165?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06249165 being conducted?

This trial has 20 study locations across Alabama, California, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atherosclerotic Cardiovascular Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atherosclerotic Cardiovascular Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.